Antivenom Market in South Korea - Manufacturing and Consumption, Outlook and Forecast 2020-2026

April 2020 | 92 pages | ID: A93668648A63EN
Market Monitor Global

Abstracts

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
This report contains market size and forecasts of Antivenom in South Korea, including the following market information:
South Korea Antivenom Market Revenue, 2015-2020, 2021-2026, ($ millions)
South Korea Antivenom Market Consumption, 2015-2020, 2021-2026, (K Vials)
South Korea Antivenom Production Capacity, 2015-2020, 2021-2026, (K Vials)
Top Five Competitors in South Korea Antivenom Market 2019 (%)
The global Antivenom market was valued at 898.9 million in 2019 and is projected to reach US$ 991.8 million by 2026, at a CAGR of 2.5% during the forecast period. While the Antivenom market size in South Korea was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antivenom manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.
This report also analyses and evaluates the COVID-19 impact on Antivenom production and consumption in South Korea

Total Market by Segment:

South Korea Antivenom Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Vials)
South Korea Antivenom Market Segment Percentages, By Type, 2019 (%)

• Polyvalent antivenom
• Monovalent antivenom

South Korea Antivenom Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Vials)
South Korea Antivenom Market Segment Percentages, By Application, 2019 (%)

• Retail Pharmacies
• Hospitals
• Others

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Antivenom Market Competitors Revenues in South Korea, by Players 2015-2020 (Estimated), ($ millions)
Total Antivenom Market Competitors Revenues Share in South Korea, by Players 2019 (%)
Total South Korea Antivenom Market Competitors Sales, by Players 2015-2020 (Estimated), (K Vials)
Total South Korea Antivenom Market Competitors Sales Market Share by Players 2019 ($ millions)
Further, the report presents profiles of competitors in the market, including the following:

• CSL Behring
• Merck & Co.
• BTG Plc
• Pfizer
• Haffkine Bio-Pharmaceutical Corporation
• Rare Disease Therapeutics
• Flynn Pharma
• Vins Bioproducts
• Bharat Serums and Vaccines

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Antivenom Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 South Korea Antivenom Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 COVID-19 IMPACT: SOUTH KOREA ANTIVENOM OVERALL MARKET SIZE

2.1 South Korea Antivenom Market Size: 2020 VS 2026
2.2 South Korea Antivenom Revenue, Prospects & Forecasts: 2015-2026
2.3 South Korea Antivenom Sales (Consumption): 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Antivenom Players in South Korea (including Foreign and Local Companies)
3.2 Top South Korea Antivenom Companies Ranked by Revenue
3.3 South Korea Antivenom Revenue by Companies (including Foreign and Local Companies)
3.4 South Korea Antivenom Sales by Companies (including Foreign and Local Companies)
3.5 South Korea Antivenom Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Antivenom Companies in South Korea, by Revenue in 2019
3.7 South Korea Manufacturers Antivenom Product Type
3.8 Tier 1, Tier 2 and Tier 3 Antivenom Players in South Korea
  3.8.1 List of South Korea Tier 1 Antivenom Companies
  3.8.2 List of South Korea Tier 2 and Tier 3 Antivenom Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - South Korea Antivenom Market Size Markets, 2020 & 2026
  4.1.2 Polyvalent antivenom
  4.1.3 Monovalent antivenom
4.2 By Type - South Korea Antivenom Revenue & Forecasts
  4.2.1 By Type - South Korea Antivenom Revenue, 2015-2020
  4.2.2 By Type - South Korea Antivenom Revenue, 2021-2026
  4.2.3 By Type - South Korea Antivenom Revenue Market Share, 2015-2026
4.3 By Type - South Korea Antivenom Sales & Forecasts
  4.3.1 By Type - South Korea Antivenom Sales, 2015-2020
  4.3.2 By Type - South Korea Antivenom Sales, 2021-2026
  4.3.3 By Type - South Korea Antivenom Sales Market Share, 2015-2026
4.4 By Type - South Korea Antivenom Price (Manufacturers Selling Prices), 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - South Korea Antivenom Market Size, 2020 & 2026
  5.1.2 Retail Pharmacies
  5.1.3 Hospitals
  5.1.4 Others
5.2 By Application - South Korea Antivenom Revenue & Forecasts
  5.2.1 By Application - South Korea Antivenom Revenue, 2015-2020
  5.2.2 By Application - South Korea Antivenom Revenue, 2021-2026
  5.2.3 By Application - South Korea Antivenom Revenue Market Share, 2015-2026
5.3 By Application - South Korea Antivenom Sales & Forecasts
  5.3.1 By Application - South Korea Antivenom Sales, 2015-2020
  5.3.2 By Application - South Korea Antivenom Sales, 2021-2026
  5.3.3 By Application - South Korea Antivenom Sales Market Share, 2015-2026
5.4 By Application - South Korea Antivenom Price (Manufacturers Selling Prices), 2015-2026

6 MANUFACTURERS & BRANDS PROFILES

6.1 CSL Behring
  6.1.1 CSL Behring Corporate Summary
  6.1.2 CSL Behring Business Overview
  6.1.3 CSL Behring Antivenom Major Product Offerings
  6.1.4 CSL Behring Sales and Revenue in South Korea (2015-2020)
  6.1.5 CSL Behring Key News
6.2 Merck & Co.
  6.2.1 Merck & Co. Corporate Summary
  6.2.2 Merck & Co. Business Overview
  6.2.3 Merck & Co. Antivenom Major Product Offerings
  6.2.4 Merck & Co. Sales and Revenue in South Korea (2015-2020)
  6.2.5 Merck & Co. Key News
6.3 BTG Plc
  6.3.1 BTG Plc Corporate Summary
  6.3.2 BTG Plc Business Overview
  6.3.3 BTG Plc Antivenom Major Product Offerings
  6.3.4 BTG Plc Sales and Revenue in South Korea (2015-2020)
  6.3.5 BTG Plc Key News
6.4 Pfizer
  6.4.1 Pfizer Corporate Summary
  6.4.2 Pfizer Business Overview
  6.4.3 Pfizer Antivenom Major Product Offerings
  6.4.4 Pfizer Sales and Revenue in South Korea (2015-2020)
  6.4.5 Pfizer Key News
6.5 Haffkine Bio-Pharmaceutical Corporation
  6.5.1 Haffkine Bio-Pharmaceutical Corporation Corporate Summary
  6.5.2 Haffkine Bio-Pharmaceutical Corporation Business Overview
  6.5.3 Haffkine Bio-Pharmaceutical Corporation Antivenom Major Product Offerings
  6.5.4 Haffkine Bio-Pharmaceutical Corporation Sales and Revenue in South Korea (2015-2020)
  6.5.5 Haffkine Bio-Pharmaceutical Corporation Key News
6.6 Rare Disease Therapeutics
  6.6.1 Rare Disease Therapeutics Corporate Summary
  6.6.2 Rare Disease Therapeutics Business Overview
  6.6.3 Rare Disease Therapeutics Antivenom Major Product Offerings
  6.6.4 Rare Disease Therapeutics Sales and Revenue in South Korea (2015-2020)
  6.6.5 Rare Disease Therapeutics Key News
6.7 Flynn Pharma
  6.6.1 Flynn Pharma Corporate Summary
  6.6.2 Flynn Pharma Business Overview
  6.6.3 Flynn Pharma Antivenom Major Product Offerings
  6.4.4 Flynn Pharma Sales and Revenue in South Korea (2015-2020)
  6.7.5 Flynn Pharma Key News
6.8 Vins Bioproducts
  6.8.1 Vins Bioproducts Corporate Summary
  6.8.2 Vins Bioproducts Business Overview
  6.8.3 Vins Bioproducts Antivenom Major Product Offerings
  6.8.4 Vins Bioproducts Sales and Revenue in South Korea (2015-2020)
  6.8.5 Vins Bioproducts Key News
6.9 Bharat Serums and Vaccines
  6.9.1 Bharat Serums and Vaccines Corporate Summary
  6.9.2 Bharat Serums and Vaccines Business Overview
  6.9.3 Bharat Serums and Vaccines Antivenom Major Product Offerings
  6.9.4 Bharat Serums and Vaccines Sales and Revenue in South Korea (2015-2020)
  6.9.5 Bharat Serums and Vaccines Key News
6.10 Serum Biotech
  6.10.1 Serum Biotech Corporate Summary
  6.10.2 Serum Biotech Business Overview
  6.10.3 Serum Biotech Antivenom Major Product Offerings
  6.10.4 Serum Biotech Sales and Revenue in South Korea (2015-2020)
  6.10.5 Serum Biotech Key News

7 ANTIVENOM PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS

7.1 Antivenom Production Capacity and Value in South Korea, Situation Analysis and Prediction, 2015-2026
  7.1.1 South Korea Antivenom Production Capacity, 2015-2026
  7.1.2 South Korea Antivenom Production 2015-2026
  7.1.3 South Korea Antivenom Production Value 2015-2026
7.2 Key Local Antivenom Manufacturers in South Korea
  7.2.1 South Korea Key Local Antivenom Manufacturers Production Capacity
  7.2.2 South Korea Key Local Antivenom Manufacturers Production
  7.2.3 South Korea Key Local Antivenom Manufacturers Production Value
  7.2.4 The Proportion of Antivenom Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
7.3 Antivenom Export and Import in South Korea
  7.3.1 South Korea Antivenom Export Market
  7.3.2 South Korea Antivenom Source of Imports

8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

8.1 PESTLE Analysis for South Korea Antivenom Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints

9 COVID-19 IMPACT ON ANTIVENOM SUPPLY CHAIN ANALYSIS

9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
  9.4.1 Marketing Channels
  9.4.2 Antivenom Distributors and Sales Agents in South Korea

10 CONCLUSION

11 APPENDIX

11.1 Note
11.2 Examples of Clients
11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Antivenom in South Korea
Table 2. Top Players in South Korea, Ranking by Revenue (2019)
Table 3. South Korea Antivenom Revenue by Companies, (US$, Mn), 2015-2020
Table 4. South Korea Antivenom Revenue Share by Companies, 2015-2020
Table 5. South Korea Antivenom Sales by Companies, (K Vials), 2015-2020
Table 6. South Korea Antivenom Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Antivenom Price (2015-2020) (USD/Vial)
Table 8. South Korea Manufacturers Antivenom Product Type
Table 9. List of South Korea Tier 1 Antivenom Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of South Korea Tier 2 and Tier 3 Antivenom Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Antivenom Revenue in South Korea (US$, Mn), 2015-2020
Table 12. By Type - Antivenom Revenue in South Korea (US$, Mn), 2021-2026
Table 13. By Type - Antivenom Sales in South Korea (K Vials), 2015-2020
Table 14. By Type - Antivenom Sales in South Korea (K Vials), 2021-2026
Table 15. By Application - Antivenom Revenue in South Korea, (US$, Mn), 2015-2020
Table 16. By Application - Antivenom Revenue in South Korea, (US$, Mn), 2021-2026
Table 17. By Application - Antivenom Sales in South Korea, (K Vials), 2015-2020
Table 18. By Application - Antivenom Sales in South Korea, (K Vials), 2021-2026
Table 19. CSL Behring Corporate Summary
Table 20. CSL Behring Antivenom Product Offerings
Table 21. CSL Behring Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 22. Merck & Co. Corporate Summary
Table 23. Merck & Co. Antivenom Product Offerings
Table 24. Merck & Co. Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 25. BTG Plc Corporate Summary
Table 26. BTG Plc Antivenom Product Offerings
Table 27. BTG Plc Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 28. Pfizer Corporate Summary
Table 29. Pfizer Antivenom Product Offerings
Table 30. Pfizer Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 31. Haffkine Bio-Pharmaceutical Corporation Corporate Summary
Table 32. Haffkine Bio-Pharmaceutical Corporation Antivenom Product Offerings
Table 33. Haffkine Bio-Pharmaceutical Corporation Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 34. Rare Disease Therapeutics Corporate Summary
Table 35. Rare Disease Therapeutics Antivenom Product Offerings
Table 36. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 37. Flynn Pharma Corporate Summary
Table 38. Flynn Pharma Antivenom Product Offerings
Table 39. Flynn Pharma Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 40. Vins Bioproducts Corporate Summary
Table 41. Vins Bioproducts Antivenom Product Offerings
Table 42. Vins Bioproducts Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 43. Bharat Serums and Vaccines Corporate Summary
Table 44. Bharat Serums and Vaccines Antivenom Product Offerings
Table 45. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 46. Serum Biotech Corporate Summary
Table 47. Serum Biotech Antivenom Product Offerings
Table 48. Serum Biotech Antivenom Sales (K Vials), Revenue (US$, Mn) and Average Price (USD/Vial) (2015-2020)
Table 49. Antivenom Production Capacity (K Vials) of Local Manufacturers in South Korea, 2015-2020
Table 50. Antivenom Production (K Vials) of Local Manufacturers in South Korea, 2015-2020
Table 51. South Korea Antivenom Production Market Share of Local Manufacturers, 2015-2020
Table 52. Antivenom Production Value (US$, Mn) of Local Manufacturers in South Korea, 2015-2020
Table 53. South Korea Antivenom Production Value Market Share of Local Manufacturers, 2015-2020
Table 54. The Percentage of Antivenom Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
Table 55. The Percentage of Antivenom Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
Table 56. Dangeguojia Antivenom Sales (Consumption), Production, Export and Import, 2015-2020
Table 57. Raw Materials and Suppliers
Table 58. Antivenom Downstream Clients in South Korea
Table 59. Antivenom Distributors and Sales Agents in South Korea

List Of Figures

LIST OF FIGURES

Figure 1. Antivenom Segment by Type
Figure 2. Antivenom Segment by Application
Figure 3. Dangeguojia Antivenom Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Antivenom Market Size in South Korea, (US$, Mn) & (K Vials): 2020 VS 2026
Figure 6. South Korea Antivenom Revenue, 2015-2026 (US$, Mn)
Figure 7. Antivenom Sales in South Korea: 2015-2026 (K Vials)
Figure 8. The Top 3 and 5 Players Market Share by Antivenom Revenue in 2019
Figure 9. By Type - South Korea Antivenom Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - South Korea Antivenom Market Share, 2015-2020
Figure 11. By Type - South Korea Antivenom Market Share, 2020-2026
Figure 12. By Type - South Korea Antivenom Price (USD/Vial), 2015-2026
Figure 13. By Application - Antivenom Revenue in South Korea (US$, Mn), 2020 & 2026
Figure 14. By Application - South Korea Antivenom Market Share, 2015-2020
Figure 15. By Application - South Korea Antivenom Market Share, 2020-2026
Figure 16. By Application -South Korea Antivenom Price (USD/Vial), 2015-2026
Figure 17. South Korea Antivenom Production Capacity (K Vials), 2015-2026
Figure 18. South Korea Antivenom Actual Output (K Vials), 2015-2026
Figure 19. South Korea Antivenom Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of South Korea Antivenom Export Destination, 2019
Figure 21. The Source of Imports of South Korea Antivenom, 2019
Figure 22. PEST Analysis for South Korea Antivenom Market in 2020
Figure 23. Antivenom Market Opportunities & Trends in South Korea
Figure 24. Antivenom Market Drivers in South Korea
Figure 25. Antivenom Market Restraints in South Korea
Figure 26. Antivenom Industry Value Chain